ChemGenex Pharmaceuticals announces that the U.S. Food and Drug Administration's (FDA) Office of Oncology Drug Products has issued a complete response letter regarding the new drug application (NDA) for OMAPRO™ (omacetaxine mepesuccinate) for the treatment of adults with chronic myeloid leukemia...